News & Events
-
Helpful Apps for People Living with Cancer
As mobile apps become more ingrained in our lives, it’s natural to look for ones that can help manage a cancer diagnosis. As for which app to choose, it really comes down to what you’re looking for...
-
Clinical Trial Phases
The four phases of lung cancer clinical trials each serve a different and important purpose. From testing the safety of a new treatment to its effectiveness and long-term outcomes... -
LUNGevity Announces $1.2M in Lung Cancer Workforce Development Research Awards
LUNGevity Foundation is proud to announce the recipients of four awards to bolster the lung cancer research workforce— the Career Development Award, the VA Research Scholar Award... -
What Is a Clinical Trial
Lung cancer clinical trials are carefully designed research studies to evaluate and learn more about new drugs and treatments. They give people the ability to participate in lung... -
KRAS Virtual Meetup
Join us the 3rd Wednesday of every month to c onnect with others who share common experiences and build your community. After registering, you will receive a confirmation email... -
Watch Recorded Expert Sessions From ILCSC
The International Lung Cancer Survivorship Conference (ILCSC) is a free virtual educational conference for people with lung cancer, caregivers, and advocates. The 2023 conference... -
Lung Cancer and NCCN Guidelines: What They Are and Why They Matter
In this expert meetup session, Carlin Callaway will review the National Comprehensive Cancer Network’s (NCCN’s) Non-Small Cell Lung Cancer (NSCLC) Guidelines and discuss how they... -
The Latest Lung Cancer Science: Highlights of WCLC 2023
I had the privilege of attending the 2023 World Conference on Lung Cancer (WCLC) in Singapore with my colleague Dr. Bellinda King-Kallimanis. WCLC, the world's largest meeting... -
Transportation to Treatment
At some point, transportation to appointments becomes a challenge for everyone. Whether it be the cost, time commitment, or finding reliable transportation, we share some tips for...
Clinical Trial Phases
Clinical Trial Phases
The four phases of lung cancer clinical trials each serve a different and important purpose. From testing the safety of a new treatment to its effectiveness and long-term outcomes, this short video explains how researchers use clinical trials for new lung cancer treatments.Phases of a Clinical Trial:1. Safety of the new treatment 2. Does the cancer respond to the treatment 3. Is this new treatment better than the current options 4. Studies the long-term benefits and side effects
What Is a Clinical Trial
What Is a Clinical Trial
Lung cancer clinical trials are carefully designed research studies to evaluate and learn more about new drugs and treatments. They give people the ability to participate in lung cancer research and access to new treatments that otherwise may not be available to them, all under the close supervision of medical experts.
Watch Recorded Expert Sessions From ILCSC
Watch Recorded Expert Sessions From ILCSC
The International Lung Cancer Survivorship Conference (ILCSC) is a free virtual educational conference for people with lung cancer, caregivers, and advocates. The 2023 conference was held September 22-23. The recorded sessions from this conference are available to registered participants through December 21, 2023, at www.lungevity.org/ilcsc. If you did not register for the conference but would like to view the recordings, you may still register for free access. The recordings are available…
Decentralized Trials: Bringing Clinical Trials Closer to the Patient
Decentralized Trials: Bringing Clinical Trials Closer to the Patient
While participating in clinical trials can provide substantial benefits to people with lung cancer, the resources required to do so may pose significant hurdles, especially to those who don’t live close to where trials are held, such as academic medical centers or major oncology network sites. Decentralized clinical trials remove some hurdles to trial participation for patients and are thus important for improving trial access for larger and more diverse groups of people. The U.S. Food and Drug…
We have succeeded in targeting KRAS G12C mutations. Now what?
We have succeeded in targeting KRAS G12C mutations. Now what?
We currently have two FDA-approved drugs, sotorasib and adagrasib, that are used to treat advanced-stage NSCLC with KRAS G12C mutations. Watch the discussion with guest speakers Rosemary Conway (patient advocate who was diagnosed with KRAS G12D-positive NSCLC) and Dr. Kathryn Arbour, MD (thoracic oncologist, assistant attending physician at Memorial Sloan Kettering Cancer Center). Dr. Arbour received a 2020 LUNGevity Career Development Award and is studying how lung cancer cells become…
Navigating Hope: How Comprehensive Biomarker Testing is Guiding Lung Cancer Care
Navigating Hope: How Comprehensive Biomarker Testing is Guiding Lung Cancer Care
Join us for a discussion on lung cancer biomarkers to learn what biomarker testing is, why it’s important, and how it can be used to optimize your treatment plans. We are thrilled to welcome our panelists: Balazs Halmos, MD, a thoracic medical oncologist from Montefiore Medical Center in New York; Elizabeth Ravera, a patient navigator at Montefiore; and a patient living with lung cancer who tested positive for the ALK biomarker. The panel is moderated by LUNGevity's Amy Moore, PhD, VP of Global…
Finding Clinical Trials for Lung Cancer: Tools and Resources
Finding Clinical Trials for Lung Cancer: Tools and Resources
Clinical trials are an important option for patients because the newest treatment approaches, not available otherwise, are being tested in them. Clinical trial research leads to more advancements and potential treatment options, and the therapies used today were once tested in clinical trials. Continued progress is only possible if patients with lung cancer volunteer to participate in the clinical trial process.
There are many ongoing clinical trials testing new lung cancer treatments,…
Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting
Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting
The development of new treatments for any disease relies on the collaborative efforts of many different stakeholders, such as scientists, clinicians, patient advocacy groups, regulators, and pharmaceutical and biotech companies.
During scientific conferences that happen throughout the year, stakeholders cobble together opportunities to discuss the current state of treatments and strategize ways to bring emerging lifesaving treatments to patients.
Each year, there is one key conference…
Ask Your Oncologist the Right Questions
Ask Your Oncologist the Right Questions
Communication is critical to a positive doctor-patient relationship. Knowing the right questions to ask helps ensure you leave your appointments with the information and answers you need. Being prepared may also lessen anxiety and help provide a sense of control. Meeting with your oncologist, especially when first diagnosed or deciding on a treatment plan, are times when being prepared with questions is necessary.
LUNGevity has downloadable lists of questions that you can bring to…
New FDA approval for KRAS G12C
New FDA approval for KRAS G12C
We want to share this KRAS Patient Gateway news alert with you.
The News
On December 12, 2022, the FDA granted accelerated approval to adagrasib for patients with KRAS G12C-mutated NSCLC. This news has been eagerly anticipated and adds to the continued excitement in the KRAS targeted therapy space following the approval of sotorasib one year ago. This approval gives yet another option to patients with KRAS G12C-positive NSCLC who have been on at least one prior systemic therapy.
In addition…
How Metastatic Brain Tumors Affect Your Lung Cancer Care
How Metastatic Brain Tumors Affect Your Lung Cancer Care
Brain metastases are known to occur in approximately 25% of patients diagnosed with lung cancer. This webinar dives into the details of brain metastasis in lung cancer to explore their signs and symptoms. It also includes a discussion of treatment considerations.
Through this webinar, you will learn to:
Understand how brain metastasis occurs
Keep an eye out for signs & symptoms of brain mets
Understand treatment options and management techniques
This webinar was created in partnership…
Understanding Pulmonary Rehab
Understanding Pulmonary Rehab
Pulmonary rehab expert Debbie Koehl, MS, RRT-NPS, AE-C, FAARC, speaks to LUNGevity's Survivorship Navigator, Kristi Griffith, to explain what pulmonary rehabilitation is, explore the benefits of pulmonary rehabilitation, and gain key insights about how to obtain pulmonary rehabilitation for yourself or a loved one. The discussion is followed by an informal Q&A with other lung cancer survivors. This recording was made during one of LUNGevity Foundation's Virtual Meetups -- a free resource…
Pneumonitis: A Common Side Effect
Pneumonitis: A Common Side Effect
In this video, nurse practitioner Lauren Welch, MSN, NP-C, AOCNP, from the Sarah Cannon Research Institute at Tennessee Oncology offers a quick review of pneumonitis - a common side effect of some lung cancer treatments. Survivors and caregivers can learn: What is pneumonitis? What causes it? How is it treated? What symptoms should we look out for?
Introduction to Radiation Therapy
Introduction to Radiation Therapy
Lung cancer survivor Jill Feldman joins radiation therapy experts Drs. Drew Moghanaki and Kristin Higgins to provide an overview of radiation therapy – including discussions of when this treatment is recommended, how the treatment is administered, and which side effects are most common.
All About Biomarker Testing & KRAS+ Lung Cancer
All About Biomarker Testing & KRAS+ Lung Cancer
Patient Rosemary Conway was joined by LUNGevity's Dr. Amy Moore and Hatim Husain, an oncologist at UCSD, to discuss biomarker testing and progress in KRAS-positive lung cancer.
Improving Treatment for KRAS-Mutant Lung Cancer
Improving Treatment for KRAS-Mutant Lung Cancer
While targeted therapies have emerged in the past decade to improve treatment of non-small cell lung cancer (NSCLC) with some types of driver mutations (such as EGFR and ALK), lung adenocarcinomas with KRAS driver mutations have been notoriously difficult to study and treat.
KRAS is just one member of a large family of proteins, called RTKs (receptor tyrosine kinases), that span from the surface of the cell into the cell’s interior. This positioning allows RTKs to detect signals (such as…
Lung Cancer Treatment Landscape: New Options and Ongoing Challenges
Lung Cancer Treatment Landscape: New Options and Ongoing Challenges
Drs. Upal Basu Roy, Amy Moore, and Dhru Deb discuss their recent publication in which they presented an analysis of the lung cancer drug pipeline. They talk about what it means for patients, new drugs under development for NSCLC and SCLC, and some of the ongoing challenges and opportunities this rapid growth means for the lung cancer community.
Newly Diagnosed with KRAS-Positive Lung Cancer?
Newly Diagnosed with KRAS-Positive Lung Cancer?
LUNGevity's Amy Moore, PhD, sits down with Mark Awad, MD, PhD, a thoracic oncologist at Dana-Farber Cancer Institute, to discuss KRAS-positive lung cancer and what questions newly diagnosed patients should ask their doctors. We discuss first-line treatment, biomarker testing, clinical trials, and drug resistance.
New Options in Adjuvant Therapy for Early-Stage NSCLC
New Options in Adjuvant Therapy for Early-Stage NSCLC
Historically, surgery has been the most effective treatment for patients with early-stage non-small cell lung cancer (NSCLC). While technological improvements, such as the development of minimally invasive techniques (such as video-assisted thoracoscopic surgery or VATS), have made surgeries safer for patients, the ability to cure early-stage NSCLC patients hasn’t improved significantly in recent decades. Even after successful surgeries that completely remove the visible tumor, about half of…
KRAS: How It Started vs. How It’s Going
KRAS: How It Started vs. How It’s Going
On May 28, 2021, the United States Food & Drug Administration (FDA) approved sotorasib as the first targeted therapy for patients with KRAS G12C-positive non-small cell lung cancer (NSCLC). Both researchers and patients celebrated this historic breakthrough, which had been a goal since the KRAS oncogene was discovered 40 years ago. KRAS is a leading driver mutation in various forms of cancer. Still, targeting KRAS had failed for nearly four decades, leading many to believe that it was “…
Immunotherapy in Early-Stage Lung Cancer
Immunotherapy in Early-Stage Lung Cancer
Upal Basu Roy, PhD, MPH, LUNGevity's Executive Director of Research, interviews Patrick Forde, MD (MB, BCH), at the 2022 AACR meeting about his findings on immunotherapy in early-stage lung cancer.
All Things KRAS: A Conversation with Terri Conneran and Dr. Darryl McConnell
All Things KRAS: A Conversation with Terri Conneran and Dr. Darryl McConnell
On January 31, 2022, Amy Moore, PhD, brought us an update on KRAS. Dr. Moore, LUNGevity's Vice President of Global Engagement and Patient Partnerships, spoke with Terri Conneran, KRAS lung cancer survivor and founder of the KRAS Kickers; and Darryl McConnell, PhD, Research Site Head at Boehringer Ingelheim in Vienna, Austria.